TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29911353

Group type: EXPERIMENTAL
Intervention: Enlarged pegboard for Braille learning
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Standard Braille
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Visually presented Braille characters (enlarged)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Visually presented Braille characters (standard size)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (non-specific tactile training)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Large tactile Braille
Number of subjects: 68
Study: 28645254

Group type: EXPERIMENTAL
Intervention: Self-collected vaginal HPV DNA specimens
Number of subjects: 150

Group type: COMPARATOR
Intervention: Provider-collected cervical HPV swabs
Number of subjects: 150
Study: 27836874

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy (CRT) activated
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cardiac resynchronisation therapy (CRT) not activated
Number of subjects: 200
Study: 25574983

Group type: EXPERIMENTAL
Intervention: 3% saline nebulization
Number of subjects: 71

Group type: COMPARATOR
Intervention: 0.9% saline nebulization
Number of subjects: 71
Study: 21907959

Group type: EXPERIMENTAL
Intervention: Imiquimod
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 56
Study: 19966323

Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 36

Group type: COMPARATOR
Intervention: Right ventricular (RV) pacing
Number of subjects: 36
Study: 18985147

Group type: EXPERIMENTAL
Intervention: Facial expressions of contempt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facial expressions of disgust
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male contemptuous faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contempt versus disgust
Number of subjects: 0
Study: 16182772

Group type: EXPERIMENTAL
Intervention: Neoral (n = 22)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Prograf (n = 25)
Number of subjects: 47
Study: 12634969

Group type: EXPERIMENTAL
Intervention: 11C-metomidate PET imaging in group A (patients free of medication)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 11C-metomidate PET imaging in group B (patients on medication)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 11C-metomidate PET imaging
Number of subjects: 11

Group type: COMPARATOR
Intervention: Medication with adrenal steroid inhibitors and chemotherapy
Number of subjects: 11
Study: 10563615

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9087160

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 micrograms aqueous nasal spray, administered twice daily for 2 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (administered twice daily for 2 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 22
Study: 1332022

Group type: EXPERIMENTAL
Intervention: Adherence intervention (Health Behavior in Cancer Prevention Model-based)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: High-fiber group
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 3842544

Group type: EXPERIMENTAL
Intervention: Low sodium water (bottled from the low sodium community distribution system with no sodium added)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High sodium water (bottled from their own community distribution system)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low sodium water (bottled from the comparison community with sodium added to the level of the high sodium community water)
Number of subjects: 0
Study: 30706571

Group type: EXPERIMENTAL
Intervention: SNP rs157582 in TOMM40 gene
Number of subjects: 2857

Group type: EXPERIMENTAL
Intervention: SNPs (APOE: rs405509, rs439401; TOMM40: rs8106922; KIBRA: rs4320284, rs11740112, rs10040267, rs13171394, rs6555802, rs2241368, rs244904, rs6555805, rs10475878)
Number of subjects: 2857

Group type: EXPERIMENTAL
Intervention: SNPs (COMT rs737865, BDNF rs1491850)
Number of subjects: 2857
Study: 29871565

Group type: EXPERIMENTAL
Intervention: Bicolumnar arthrodesis
Number of subjects: 12

Group type: COMPARATOR
Intervention: Radioscapholunate arthrodesis
Number of subjects: 12
Study: 27571238

Group type: EXPERIMENTAL
Intervention: EquiaFil with Equia Coat
Number of subjects: 54

Group type: COMPARATOR
Intervention: Riva SC with Fuji Varnish
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: EquiaFil
Number of subjects: 54

Group type: COMPARATOR
Intervention: Riva SC
Number of subjects: 54
Study: 24738835

Group type: EXPERIMENTAL
Intervention: SuperQuant
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ultrio
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ultrio Plus
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: MPX
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ultrio Plus and MPX
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: At least two assays
Number of subjects: 135
Study: 22309881

Group type: EXPERIMENTAL
Intervention: Autonomy-supportive dental intervention
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 141
Study: 19640359

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 17636088

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (no CBT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (no fluoxetine)
Number of subjects: 116
Study: 15732870

Group type: EXPERIMENTAL
Intervention: BDX mixed with PRP
Number of subjects: 13

Group type: COMPARATOR
Intervention: BDX alone
Number of subjects: 13
Study: 11157186

Group type: EXPERIMENTAL
Intervention: Distal balloon protection during carotid stenting
Number of subjects: 8

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 8
Study: 8102913

Group type: EXPERIMENTAL
Intervention: Topical tiacrilast 3% hydrogel
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 32
Study: 2893778

Group type: EXPERIMENTAL
Intervention: 2 mg tulobuterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 mg salbutamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.5 mg terbutaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta 2-agonists during strong contraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous beta 2-sympathomimetic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29436320

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitisation and Reprocessing (EMDR) therapy
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 85
Study: 28387058

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 767

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 767
Study: 26271221

Group type: EXPERIMENTAL
Intervention: Water session (200 ml water with breakfast, 750 ml water over 2 hours)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control session (no water after breakfast)
Number of subjects: 52
Study: 23277532

Group type: EXPERIMENTAL
Intervention: Paced heart rate of 80 b.p.m.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Paced heart rate of 60 b.p.m.
Number of subjects: 10
Study: 21331651

Group type: EXPERIMENTAL
Intervention: High-flexion cruciate substituting (PS) knee
Number of subjects: 95

Group type: COMPARATOR
Intervention: High-flexion cruciate retaining (CR) knee
Number of subjects: 95
Study: 18230798

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoendocrine therapy
Number of subjects: 2732

Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 2732
Study: 16879682

Group type: EXPERIMENTAL
Intervention: Millin modified retropubic prostatectomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Classical transvesical prostatectomy
Number of subjects: 62
Study: 14684712

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 444

Group type: COMPARATOR
Intervention: Control group (Fluoxetine and Nortriptyline)
Number of subjects: 444
Study: 11195032

Group type: EXPERIMENTAL
Intervention: Isotonic Ems salt solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution
Number of subjects: 40
Study: 9248588

Group type: EXPERIMENTAL
Intervention: 1 ml of 50% glycerol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2 ml of 0.5% bupivacaine
Number of subjects: 15
Study: 8340208

Group type: EXPERIMENTAL
Intervention: Cross‐design synthesis strategy
Number of subjects: 0
Study: 3499246

Group type: EXPERIMENTAL
Intervention: 17/25/1 cold-adapted reassortant vaccine
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: CR 59 cold-adapted reassortant vaccine
Number of subjects: 170
Study: 31838405

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 556

Group type: COMPARATOR
Intervention: Erlotinib/gefitinib
Number of subjects: 556
Study: 30566020

Group type: EXPERIMENTAL
Intervention: Height (as a risk factor)
Number of subjects: 493519

Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis for height
Number of subjects: 493519
Study: 29178852

Group type: EXPERIMENTAL
Intervention: Couple-oriented post-test HIV counseling
Number of subjects: 711
Study: 26267253

Group type: EXPERIMENTAL
Intervention: COMPAS intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study: 24035507

Group type: EXPERIMENTAL
Intervention: CPRmeter feedback device (group G)
Number of subjects: 144
Study: 20797696

Group type: EXPERIMENTAL
Intervention: Speech task
Number of subjects: 60

Group type: COMPARATOR
Intervention: Reading task
Number of subjects: 60
Study: 19767092

Group type: EXPERIMENTAL
Intervention: Dose-dense paclitaxel (80 mg/m²; 1-h intravenous infusion) plus carboplatin (AUC 6 mg/mL per min) on day 1 of a 21-day cycle; n=312
Number of subjects: 631

Group type: COMPARATOR
Intervention: Conventional regimen: Paclitaxel (180 mg/m²; 3-h intravenous infusion) plus carboplatin (AUC 6 mg/mL per min) on day 1 of a 21-day cycle; n=319
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Dose-dense regimen
Number of subjects: 631

Group type: COMPARATOR
Intervention: Conventional regimen
Number of subjects: 631
Study: 17224859

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose transdermal estradiol (0.014 mg/d)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 15097957

Group type: EXPERIMENTAL
Intervention: Combination therapy of narrowband UVB plus cream PUVA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cream PUVA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Narrowband UVB
Number of subjects: 30
Study: 9525297

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy combined with anti-tuberculosis chemotherapy (n=17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Anti-tuberculosis chemotherapy only (n=17)
Number of subjects: 34
Study: 8083624

Group type: EXPERIMENTAL
Intervention: Vertical Pulsating Stimulation (VPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no VPS)
Number of subjects: 0
Study: 2979691

Group type: EXPERIMENTAL
Intervention: Caved-S two tablets twice daily
Number of subjects: 95

Group type: COMPARATOR
Intervention: Ranitidine 150 mg at night
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Combined therapy (Caved-S + Ranitidine)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Post-maintenance therapy
Number of subjects: 95
Study: 28958744

Group type: EXPERIMENTAL
Intervention: Emergency department/home environmental control intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caregiver worry about medication side effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allergic rhinitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 or more primary care provider asthma visits within the past 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asthma control assessed during fall or spring season
Number of subjects: 0
Study: 26990147

Group type: EXPERIMENTAL
Intervention: Live Lactobacillus rhamnosus GG
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Heat-inactivated Lactobacillus rhamnosus GG
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control juice (placebo)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Correlation of HRV load with symptom scores
Number of subjects: 59
Study: 25424821

Group type: EXPERIMENTAL
Intervention: HAVpur Junior
Number of subjects: 0

Group type: COMPARATOR
Intervention: Havrix 720 Junior
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both vaccines
Number of subjects: 0
Study: 22965298

Group type: EXPERIMENTAL
Intervention: JASPER treatment (30 min, twice weekly for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (30 h of ABA-based therapy per week)
Number of subjects: 0
Study: 19910882

Group type: EXPERIMENTAL
Intervention: Care Management Intervention
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1202
Study: 18585531

Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 433

Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 433

Group type: COMPARATOR
Intervention: Antidepressant medication
Number of subjects: 433
Study: 16958964

Group type: EXPERIMENTAL
Intervention: Regular pattern of trial medication intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional prescribed medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not smoking
Number of subjects: 0
Study: 12505938

Group type: EXPERIMENTAL
Intervention: Propofol-N2O anesthesia
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no propofol, no N2O)
Number of subjects: 36
Study: 10364996

Group type: EXPERIMENTAL
Intervention: Zero deadspace tracheal tube (ZEDS‐TT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Single-lumen tracheal tube
Number of subjects: 11
Study: 8644687

Group type: EXPERIMENTAL
Intervention: Butter
Number of subjects: 8

Group type: COMPARATOR
Intervention: Tallow
Number of subjects: 8
Study: 1899797

Group type: EXPERIMENTAL
Intervention: Oxyquinoline ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Desitin or A & D ointment (Control)
Number of subjects: 0
Study: 6239292

Group type: EXPERIMENTAL
Intervention: Fenoterol hydrobromide (200 micrograms) plus ipratropium bromide (80 micrograms) delivered by standard aerosol inhaler
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fenoterol hydrobromide (200 micrograms) plus ipratropium bromide (80 micrograms) delivered by inhaler with extension tube spacer
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 30624371

Group type: EXPERIMENTAL
Intervention: Vigorous aerobic exercise training (AET)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy controls (sedentary women, n = 19)
Number of subjects: 18
Study: 28925580

Group type: EXPERIMENTAL
Intervention: Education intervention including nutrition, stimulation, sanitation, and hygiene
Number of subjects: 511

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 511
Study: 26351971

Group type: EXPERIMENTAL
Intervention: Surfactant (100 mg/kg) and Budesonide (0.25 mg/kg)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Surfactant only (100 mg/kg)
Number of subjects: 265
Study: 24457276

Group type: EXPERIMENTAL
Intervention: Nicorandil (6 mg bolus injection before PCI and 6 mg/hour infusion for 24 hours)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (no nicorandil)
Number of subjects: 62
Study: 23032159

Group type: EXPERIMENTAL
Intervention: MenACWY‐TT
Number of subjects: 304

Group type: COMPARATOR
Intervention: MenC‐CRM 197
Number of subjects: 304
Study: 20846797

Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Number of subjects: 0
Study: 17182160

Group type: EXPERIMENTAL
Intervention: TBI patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study: 15515998

Group type: EXPERIMENTAL
Intervention: Non-closure of both visceral and parietal peritoneum (Group A)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Non-closure of only visceral peritoneum (Group B)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Closure of both visceral and parietal peritoneum (Group C)
Number of subjects: 360
Study: 11559453

Group type: EXPERIMENTAL
Intervention: DRSP/EE (drospirenone 3 mg and ethinyl estradiol 30 microg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: DRSP/EE
Number of subjects: 82
Study: 9760324

Group type: EXPERIMENTAL
Intervention: Chicken broth (CB: 109.5 mmol/l Na, 25.3 mmol/l K)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chicken noodle soup (Soup: 333.8 mmol/l Na, 13.7 mmol/l K)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water (H2O)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Carbohydrate‐electrolyte drink (CE: 16.0 mmol/l Na, 3.3 mmol/l K)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte drink (CE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chicken broth (CB) and Chicken noodle soup (Soup)
Number of subjects: 30
Study: 7826904

Group type: EXPERIMENTAL
Intervention: CMFp (Cyclophosphamide-Methotrexate-Fluorouracil plus low-dose continuous prednisone)
Number of subjects: 1601

Group type: EXPERIMENTAL
Intervention: CMFp plus surgical oophorectomy
Number of subjects: 1601

Group type: EXPERIMENTAL
Intervention: Combined chemoendocrine therapy (CMFp plus tamoxifen)
Number of subjects: 1601

Group type: EXPERIMENTAL
Intervention: p + T (prednisone plus tamoxifen)
Number of subjects: 1601
Study: 3377464

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (500 mg each) administered intravenously
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (500 mg each) administered intraperitoneally
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cilastatin
Number of subjects: 6
Study: 31233464

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m/dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vincristine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 20
Study: 28641838

Group type: EXPERIMENTAL
Intervention: DAPT for 6 months
Number of subjects: 3773

Group type: COMPARATOR
Intervention: DAPT for 18 months
Number of subjects: 3773
Study: 25026950

Group type: EXPERIMENTAL
Intervention: Interaction with a bipolar virtual patient (VP)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Completion of a video-teaching module
Number of subjects: 67
Study: 24156500

Group type: EXPERIMENTAL
Intervention: Nutrition training for mid-level providers (MLPs) using WHO guidelines; duration: 6 months.
Number of subjects: 800
Study: 21564041

Group type: EXPERIMENTAL
Intervention: GlideScope®
Number of subjects: 75

Group type: COMPARATOR
Intervention: Flexible fibreoptic bronchoscope
Number of subjects: 75
Study: 19235866

Group type: EXPERIMENTAL
Intervention: High-dose interferon-alpha-2b (10 MU) with ribavirin (RBV)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard dose interferon-alpha-2b (6 MU) with ribavirin (RBV)
Number of subjects: 200
Study: 15961759

Group type: EXPERIMENTAL
Intervention: MEC plus lintuzumab (12 mg/m2)
Number of subjects: 191

Group type: COMPARATOR
Intervention: MEC alone
Number of subjects: 191
Study: 11988245

Group type: EXPERIMENTAL
Intervention: Whispered voice test
Number of subjects: 32656

Group type: EXPERIMENTAL
Intervention: Whispered voice test after wax removal
Number of subjects: 32656

Group type: EXPERIMENTAL
Intervention: Hearing aid ownership
Number of subjects: 32656

Group type: EXPERIMENTAL
Intervention: Hearing aid usage
Number of subjects: 32656
Study: 9579266

Group type: EXPERIMENTAL
Intervention: Servo Ventilator 300
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VIP Bird
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SLE 2000 Neonatal Ventilator
Number of subjects: 20

Group type: COMPARATOR
Intervention: SLE 2000
Number of subjects: 20
Study: 8749876

Group type: EXPERIMENTAL
Intervention: Isoproterenol administration during tilt test
Number of subjects: 44
Study: 2702512

Group type: EXPERIMENTAL
Intervention: Inhaled lignocaine (40 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (phosphate-buffered saline)
Number of subjects: 8
Study: 139671

Group type: EXPERIMENTAL
Intervention: Stanozolol (an anabolic steroid), orally active, duration 4 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31373901

Group type: EXPERIMENTAL
Intervention: Web-based preoperative and postoperative patient care education
Number of subjects: 305

Group type: COMPARATOR
Intervention: Traditional education
Number of subjects: 305
Study: 28031707

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (B/F) 320/9 μg, twice daily
Number of subjects: 1571
Study: 25237170

Group type: EXPERIMENTAL
Intervention: Suture anchor technique
Number of subjects: 45

Group type: COMPARATOR
Intervention: Suture bridge technique
Number of subjects: 45
Study: 23507459

Group type: EXPERIMENTAL
Intervention: Normative information about college drinking
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control condition (no normative information)
Number of subjects: 80
Study: 21520106

Group type: EXPERIMENTAL
Intervention: Preoperative crooked noses
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Postoperative crooked noses
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal noses
Number of subjects: 40
Study: 19371522

Group type: EXPERIMENTAL
Intervention: Intravenous octreotide (100 microg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravenous prochlorperazine (10 mg)
Number of subjects: 44
Study: 16896118

Group type: EXPERIMENTAL
Intervention: Levamisole (administered bimonthly)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 350
Study: 15019669

Group type: EXPERIMENTAL
Intervention: On-pump surgery
Number of subjects: 35

Group type: COMPARATOR
Intervention: Off-pump surgery
Number of subjects: 35